Acorda Therapeutics ACOR Stock
Acorda Therapeutics Price Chart
Acorda Therapeutics ACOR Financial and Trading Overview
Acorda Therapeutics stock price | 0.66 USD |
Previous Close | 12.1 USD |
Open | 11.37 USD |
Bid | 0 USD x 2200 |
Ask | 0 USD x 900 |
Day's Range | 10.55 - 12.33 USD |
52 Week Range | 5.2 - 24.8 USD |
Volume | 47.67K USD |
Avg. Volume | 53.17K USD |
Market Cap | 14.48M USD |
Beta (5Y Monthly) | 1.37183 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
ACOR Valuation Measures
Enterprise Value | 161.33M USD |
Trailing P/E | N/A |
Forward P/E | -12.395833 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.122418396 |
Price/Book (mrq) | 0.18816312 |
Enterprise Value/Revenue | 1.364 |
Enterprise Value/EBITDA | -64.327 |
Trading Information
Acorda Therapeutics Stock Price History
Beta (5Y Monthly) | 1.37183 |
52-Week Change | -7.031% |
S&P500 52-Week Change | 20.43% |
52 Week High | 24.8 USD |
52 Week Low | 5.2 USD |
50-Day Moving Average | 11.76 USD |
200-Day Moving Average | 12.7 USD |
ACOR Share Statistics
Avg. Volume (3 month) | 53.17K USD |
Avg. Daily Volume (10-Days) | 71.15K USD |
Shares Outstanding | 1.22M |
Float | 1.19M |
Short Ratio | 0.1 |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | 11.59K |
Short % of Float | 0.95% |
Short % of Shares Outstanding | 0.94% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -49.21% |
Operating Margin (ttm) | -29.24% |
Gross Margin | 71.78% |
EBITDA Margin | -2.12% |
Management Effectiveness
Return on Assets (ttm) | -5.41% |
Return on Equity (ttm) | -56.93% |
Income Statement
Revenue (ttm) | 118.29M USD |
Revenue Per Share (ttm) | 105.25 USD |
Quarterly Revenue Growth (yoy) | -1.19% |
Gross Profit (ttm) | 82.43M USD |
EBITDA | -2508000 USD |
Net Income Avi to Common (ttm) | -58218000 USD |
Diluted EPS (ttm) | -49.55 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 30.26M USD |
Total Cash Per Share (mrq) | 24.86 USD |
Total Debt (mrq) | 177.11M USD |
Total Debt/Equity (mrq) | 230.13 USD |
Current Ratio (mrq) | 1.96 |
Book Value Per Share (mrq) | 63.243 |
Cash Flow Statement
Operating Cash Flow (ttm) | -14305000 USD |
Levered Free Cash Flow (ttm) | 14.98M USD |
Profile of Acorda Therapeutics
Country | United States |
State | NY |
City | Pearl River |
Address | 2 Blue Hill Plaza |
ZIP | 10965 |
Phone | 914 347 4300 |
Website | https://www.acorda.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 111 |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Q&A For Acorda Therapeutics Stock
What is a current ACOR stock price?
Acorda Therapeutics ACOR stock price today per share is 0.66 USD.
How to purchase Acorda Therapeutics stock?
You can buy ACOR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Acorda Therapeutics?
The stock symbol or ticker of Acorda Therapeutics is ACOR.
Which industry does the Acorda Therapeutics company belong to?
The Acorda Therapeutics industry is Drug Manufacturers-Specialty & Generic.
How many shares does Acorda Therapeutics have in circulation?
The max supply of Acorda Therapeutics shares is 1.24M.
What is Acorda Therapeutics Price to Earnings Ratio (PE Ratio)?
Acorda Therapeutics PE Ratio is 0.00000000 now.
What was Acorda Therapeutics earnings per share over the trailing 12 months (TTM)?
Acorda Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Acorda Therapeutics company belong to?
The Acorda Therapeutics sector is Healthcare.
Acorda Therapeutics ACOR included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
NASDAQ Biotechnology Total Retu XNBI | 4469.42 USD — |
-1.87
|
— — | 4461.55 USD — | 4528.54 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 8098.63 USD — |
-5.98
|
— — | 8089.65 USD — | 8265.47 USD — | — - | — — |
- {{ link.label }} {{link}}